|1.||Grosset, Jacques H: 13 articles (04/2015 - 02/2004)|
|2.||Tyagi, Sandeep: 12 articles (04/2015 - 06/2002)|
|3.||Miravitlles, Marc: 12 articles (01/2015 - 01/2003)|
|4.||Arvis, Pierre: 12 articles (01/2015 - 05/2003)|
|5.||Arvis, P: 11 articles (02/2013 - 01/2001)|
|6.||Nuermberger, Eric L: 10 articles (07/2015 - 02/2004)|
|7.||Choudhri, Shurjeel: 10 articles (08/2009 - 01/2004)|
|8.||Acharya, Nisha R: 9 articles (06/2014 - 01/2012)|
|9.||Srinivasan, Muthiah: 9 articles (06/2014 - 01/2012)|
|10.||Rajaraman, Revathi: 9 articles (06/2014 - 01/2012)|
01/01/2014 - "Moxifloxacin administered for a mean of 10.0 days (range: 2.0 to 39.0 days) was highly effective: 96.7% of patients in the efficacy population (n=2152) improved and 93.2% were cured of infection during the study. "
03/01/2004 - "Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections."
01/01/2011 - "Prolonged antitubercular therapy, possibly including moxifloxacin, appears to be beneficial in the treatment of central nervous system tuberculous infections."
02/01/2012 - "Moxifloxacin is an effective and relatively safe option for the treatment of patients with intra-abdominal infections. "
03/01/2011 - "Clinical reports suggest that moxifloxacin may be effective for the treatment of odontogenic infections that can lead to serious complications. "
07/01/2010 - "The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic, with beta-lactam-based standard therapy, which has been reported to possess good efficacy for community-acquired pneumonia (CAP). "
05/15/2008 - "Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial."
01/01/2014 - "Moxifloxacin is effective and safe for treatment of community-acquired pneumonia with aspiration factors. "
05/01/2005 - "Our objective was to study to what extent MV could influence the efficacy of moxifloxacin in a rabbit model of pneumonia. "
08/01/2010 - "Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp."
08/01/2010 - "H2O2 exposure did not increase cellular toxicity Vigamox did not show significant toxicity on primary RPEs, TMCs, LECs, CECs, or human corneal endothelium at concentrations up to 150 microg/ml. The MIC90 of moxifloxacin for pathogens commonly encountered in endophthalmitis is known to be in the range of 0.25-2.5 microg/ml. Therefore, intracameral use of Vigamox at concentrations up to 150 microg/ml may be safe and effective for preventing endophthalmitis after intraocular surgery."
03/01/2008 - "No significant toxicity of moxifloxacin was seen on primary RPE cells, ARPE19 cells, or ONHA cells at concentrations up to 150 microg/mL. Intravitreal use of moxifloxacin up to this concentration may be safe and effective for the treatment of endophthalmitis."
09/01/2005 - "Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model."
08/01/2010 - "[Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? "
06/01/2009 - "This study showed no significant toxicity for moxifloxacin on CEC, TMC, RPE cells, or human corneal endothelium for concentrations up to 150 microg/mL. The minimum inhibitory concentration of moxifloxacin to inhibit 90% of pathogens commonly encountered in endophthalmitis is known to be in the range of 0.25-2.5 microg/mL. Therefore, prophylactic intracameral use of moxifloxacin at concentrations up to 150 microg/mL may be safely used to prevent endophthalmitis after intraocular surgery."
01/01/2007 - "[Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis]."
09/01/2001 - "The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience."
01/01/2013 - "AVANTI (AVelox® in Acute Exacerbations of chroNic bronchiTIs) was a prospective, observational study conducted in eight Eastern European countries in patients > 35 years with AECB/AECOPD to whom moxifloxacin was prescribed. "
01/01/2013 - "Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)."
07/01/2012 - "The Moxifloxacin in Acute Exacerbations of Chronic Bronchitis TriaL (MAESTRAL) was a multiregional, randomised, double-blind non-inferiority outpatient study. "
|5.||Respiratory Tract Infections (Respiratory Tract Infection)
04/01/2009 - "Moxifloxacin (MXF) is a fluoroquinolone antibiotic that is effective against respiratory infections. "
12/01/1999 - "12 mg/L) and indicate that moxifloxacin should be effective in the treatment of community-acquired, lower respiratory tract infections."
05/01/2004 - "Once-daily oral moxifloxacin 400 mg was shown to be safe and effective in this trial for the treatment of respiratory tract infections of suspected bacterial origin in the clinical practice setting."
03/01/2005 - "[Efficacy of moxifloxacin in the treatment of respiratory tract infections: the Croatian post-marketing study]."
12/01/2003 - "In the present study, we examined the lung tissue diffusion of moxifloxacin at a dose of 400 mg administered intravenously or orally once-daily, and the results were correlated to microbiological data to estimate the clinical efficacy of moxifloxacin in lower community-acquired respiratory infections. "
|5.||7- ((3R)- aminohexahydro- 1H- azepin- 1- yl)- 8- chloro- 1- cyclopropyl- 6- fluoro- 1,4- dihydro- 4- oxo- 3- quinolinecarboxylic acid
|2.||Drug Therapy (Chemotherapy)